SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-010607
Filing Date
2022-05-25
Accepted
2022-05-25 08:44:26
Documents
14
Period of Report
2022-05-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K impl-20220525.htm   iXBRL 8-K 54414
2 EX-99.1 impl-ex99_1.htm EX-99.1 471
3 PDF COURTESY COPY impl-ex99_1.pdf EX-99.1 1180574
  Complete submission text file 0000950170-22-010607.txt   1776522

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20220525_lab.xml EX-101.LAB 13438
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20220525.xsd EX-101.SCH 2480
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20220525_pre.xml EX-101.PRE 9926
8 EXTRACTED XBRL INSTANCE DOCUMENT impl-20220525_htm.xml XML 4716
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 22958951
SIC: 2834 Pharmaceutical Preparations